Powered 500 · 2026POWEREDS. 446 of 500
Lewis steered Insmed through the notoriously difficult clinical-to-commercial transition, building a rare-disease business around Arikayce while advancing brensocatib — a potential first-in-class bronchiectasis treatment — at a stage when peer companies repeatedly stumbled.
Will Lewis is Chair and CEO of Insmed, a biopharmaceutical company focused on serious and rare diseases.
Insmed's approved products include Arikayce for refractory Mycobacterium avium complex lung disease and Brinsupri (brensocatib), which the FDA approved in August 2025 as the first and only therapy for non-cystic fibrosis bronchiectasis. Under Lewis's leadership, Insmed has grown from a small clinical-stage company into a commercial-stage rare disease business with multiple approved therapies, navigating complex regulatory pathways and specialty commercialization across multiple cycles.
Interview · In Pipeline
Sponsored placement
An invitation, extended to Powered readers.
Drive the Continental GT S.
Request a test driveBentley T&Cs apply
